Third-quarter sales of Regeneron's Eylea rise 12 percent

Regeneron Pharmaceuticals announced Wednesday that third-quarter sales of Eylea in the US climbed 12 percent year-over-year to $953 million, topping analyst expectations of $935 million. Overall revenue in the three-month period surged 23 percent to $1.5 billion, while net income jumped 46 percent to $388 million. 

Regeneron CEO Leonard Schleifer remarked "in the third quarter, [we] made significant progress with our commercialised medicines, including continued strong global sales for our retinal therapy Eylea and the completion of enrolment in our Phase 3 PANORAMA study in diabetic retinopathy, which represents an important new potential indication for Eylea." Schleifer added "we also saw robust US launch progress with Dupixent in moderate-to-severe atopic dermatitis, and a favourable US appellate court ruling for Praluent in our ongoing PCSK9 antibody litigation." 

In the quarter, sales of the cholesterol drug Praluent, which is partnered with Sanofi, totalled $49 million, up from $38 million in the third quarter of 2016 but short of analyst forecasts of $54 million. Last month, a US appeals court overturned a lower court decision barring the drugmakers from marketing, selling or manufacturing Praluent and ordered a new trial. 

FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

Meanwhile, revenue from Dupixent, which is also partnered with Sanofi, reached $89 million in the three-month period. The therapy, which was initially cleared in the US in March, was approved by regulators in Europe for use in patients with moderate-to-severe atopic dermatitis in September. 

Additionally, Regeneron recorded $3 million in sales for the rheumatoid arthritis therapy Kevzara. The treatment, which is co-marketed by Sanofi, was approved by regulators in the US, EU and Japan this year. For related analysis, read ViewPoints: Pricing strategy comes to the fore for Regeneron, Sanofi's newest entrant in the RA market.

To read more Top Story articles, click here.